2024-11-23 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**1. Performance Comparison and Alpha/Beta Analysis:**

Merck & Co Inc (MRK) is a leading pharmaceutical company known for its diverse portfolio of prescription medicines, vaccines, and animal health products.

The cumulative return of MRK (68.12%) significantly lags behind the S&P 500 (VOO) cumulative return (127.58%) over the analyzed period.  The difference is -59.46%, placing it at the 7.34 percentile of its historical performance relative to the S&P 500 (based on provided min/max range).  This suggests underperformance compared to the broader market.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|------|
| 2015-2017  | 8.2% | 15.6% | -30.2% | 0.9 | 135.8 |
| 2016-2018  | 59.7% | 15.6% | 27.4% | 0.7 | 184.4 |
| 2017-2019  | 65.0% | 15.6% | 13.3% | 0.7 | 219.5 |
| 2018-2020  | 58.9% | 25.8% | 11.6% | 0.7 | 197.4 |
| 2019-2021  | 16.7% | 25.8% | -83.3% | 0.6 | 193.9 |
| 2020-2022  | 39.4% | 25.8% | 15.8% | 0.5 | 280.7 |
| 2021-2023  | 55.2% | 19.5% | 20.2% | 0.3 | 275.8 |
| 2022-2024  | 39.5% | 25.6% | 9.4% | 0.3 | 252.6 |

The Alpha values fluctuate significantly, indicating periods of both outperformance and underperformance relative to the benchmark. The Beta consistently remains below 1, suggesting lower volatility than the S&P 500.


**2. Recent Price Movement:**

* **Last Close:** $99.16
* **5-Day Moving Average:** $97.91
* **20-Day Moving Average:** $100.37
* **60-Day Moving Average:** $108.52

The price is currently below all three moving averages, indicating a short-term downtrend.


**3. Technical Indicators and Expected Return:**

* **RSI:** 40.48 (Approaching oversold territory, suggesting potential bounce)
* **PPO:** 0.24 (Positive, but relatively low, indicating weak momentum)
* **20-Day Relative Divergence:** -12.24% (Short-term bearish divergence)
* **Expected Return:** 0.0% (The provided expected return is 0%, suggesting no significant projected outperformance against the S&P 500 over the long term.  Further analysis is required to determine the validity of this figure.)

The current price of $99.16 doesn't show signs of a significant sudden price movement (neither a sharp upward or downward trend) based on the provided data.  Additional analysis is needed to confirm this.


**4. Recent Financials:**

| Date       | EPS    | Revenue     |
|------------|--------|-------------|
| 2024-11-06 | 1.25   | $16.66 B    |
| 2024-08-05 | 2.15   | $16.11 B    |
| 2024-05-03 | 1.88   | $15.78 B    |
| 2023-11-03 | 1.87   | $15.96 B    |
| 2024-11-06 | 1.87   | $15.96 B    | *(Duplicate entry)*

There is a duplicate entry for 2024-11-06.  EPS shows some volatility, requiring further investigation into the reasons behind the fluctuations.  A comparison with analyst expectations for the most recent quarter (Nov 6, 2024) is crucial for a complete assessment.


**6. Financial Information:**

**1) Revenue and Profitability:**

| Quarter    | Revenue     | Profit Margin |
|------------|-------------|---------------|
| 2024-09-30 | $16.66B     | 75.51%        |
| 2024-06-30 | $16.11B     | 76.76%        |
| 2024-03-31 | $15.78B     | 77.56%        |
| 2023-12-31 | $14.63B     | 73.26%        |
| 2023-09-30 | $15.96B     | 73.29%        |

Profit margins are generally high and consistent, indicating strong profitability.


**2) Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2024-09-30 | $44.50B   | 7.09%     |
| 2024-06-30 | $43.58B   | 12.52%    |
| 2024-03-31 | $40.36B   | 11.80%    |
| 2023-12-31 | $37.58B   | -3.26%    |
| 2023-09-30 | $41.25B   | 11.50%    |

ROE fluctuates, with a negative value in Q4 2023, warranting further investigation.


**7. News and Recent Issues:**

*(This section requires access to real-time news sources like Shacknews and FINBOLD to provide an accurate analysis of recent earnings news, analyst opinions, and market outlook.  Please provide this information for a complete report.)*


**8. Overall Analysis:**

MRK has shown inconsistent performance relative to the S&P 500, with periods of both outperformance and underperformance.  While profitability is strong, recent EPS figures are volatile, and the most recent results require comparison with analyst expectations for a comprehensive evaluation.  The stock is currently trading below its moving averages, suggesting a bearish trend in the short term.  Technical indicators show a mixed picture, with RSI suggesting potential for a bounce, while PPO indicates weak momentum.  A comprehensive assessment requires further analysis of recent news, analyst opinions, and a deeper dive into the factors driving EPS volatility. The provided 0% expected return needs further substantiation.  Long-term investment requires careful consideration of these factors.


**9. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investing in the stock market involves inherent risks.  Consult a financial professional before making any investment decisions.
